Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 15/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 5/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19785516 | 1.00 | PTPN11 (0.50) | PTPN11KCNH2RETMAPK3MAPK1 | |
| SCHEMBL21115108 | 0.89 | PTPN11 (0.55) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL19785424 | 0.89 | PTPN11 (0.53) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL30455265 | 0.85 | HDAC3 (0.55) | PTPN11KCNH2RETMAPK3MAPK1 | |
| SCHEMBL19785495 | 0.85 | HDAC3 (0.55) | PTPN11KCNH2RETMAPK3MAPK1 | |
| SCHEMBL25514156 | 0.82 | PTPN11 (0.63) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL16926364 | 0.82 | PTPN11 (0.66) | PTPN11KCNH2 | |
| SCHEMBL29689685 | 0.82 | PTPN11 (0.66) | PTPN11KCNH2 | |
| SCHEMBL21115172 | 0.82 | PTPN11 (0.46) | PTPN11KCNH2 | |
| SCHEMBL30531722 | 0.81 | PTPN11 (0.67) | PTPN11KCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| EP-4302834-A2 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | PTPN11 12/4885KCNH2 3436/4885RET 82/4885 |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885KCNH2 2485/4885RET 76/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | PTPN11 6/4885KCNH2 1681/4885RET 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.